<DOC>
	<DOCNO>NCT00008528</DOCNO>
	<brief_summary>The purpose study compare change viral load ( amount HIV blood ) patient receive T-20 select anti-HIV drug patient receive select anti-HIV drug .</brief_summary>
	<brief_title>T-20 With Anti-HIV Combination Therapy Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance Each Three Classes Approved Anti-HIV Drugs</brief_title>
	<detailed_description>Eligible patient remain pre-study regimen baseline . An OB regimen choose physician patient base patient 's prior treatment history , prior current laboratory abnormality , screen GT/PT antiretroviral resistance testing , prior GT/PT antiretroviral resistance ( available ) . The drug OB regimen choose among currently approve antiretrovirals permit newly approved/investigational antiretrovirals available country study implement , must consist 3 5 drug , include 1 newly approved/investigational agent . Patients stratify respect viral load use ( versus non-use ) allow newly approved/investigational antiretrovirals . Patients randomize receive 1 follow 2 treatment 48 week : OB OB plus T-20 . Patients follow assess viral load , safety , antiretroviral resistance , T-20 pharmacokinetics , quality life . At end 48 week treatment patient allow ( ) roll receive OB plus T-20 ( patient receive OB regimen alone ) ( b ) continue take OB plus T-20 ( patient already receive OB plus T-20 ) , additional 48 week ( plus 4 week safety follow-up period ) , 12 week commercial availability T-20 country treat , whichever come first . All patient follow study maximum 100 week initial baseline visit date .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVinfected . Are least 16 year old ( consent parent guardian 18 ) . Have viral load ( level HIV blood ) 5,000 copies/ml . Have receive antiHIV drug least 6 month and/or show resistance 3 type antiHIV drug follow : nucleoside reverse transcriptase inhibitor ( resistant 1 ) ; nonnucleoside reverse transcriptase inhibitor ( resistant 1 ) ; protease inhibitor ( resistant 2 , take either together 1 least 6 month total ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Drug Resistance , Microbial</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Membrane Fusion</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>